Latest From Angiochem Inc.
Pipeline Watch has been updated to bring greater depth and detail to a potential therapeutic product’s progress through the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.
Concerned about chronic liver injury, FDA halts development of Geron’s telomerase inhibitor imetelstat, the only drug left standing in Geron’s pipeline, and requests data for patients who discontinued treatment in Geron-sponsored plus non-Geron studies.
The good news for Geron's investors? Now that the Menlo Park, California-based company has terminated development of GRN1005 and plans to lay off 64 of its 107 employees, it has enough cash on hand to fund its operations for two or three years.
- Large Molecule
- Therapeutic Areas
- Metabolic Disorders
- Neurology, Nervous System
- North America
- Parent & Subsidiaries
- Angiochem Inc.
- Senior Management
Jean-Paul Castaigne, MD, Pres. & CEO
Betty Lawrence, VP, Dev.
Dejan Ristic, Acting Head, Fin.
Catherine Gagnon, Dir., Corp. Dev.
Jean E Lachowicz, PhD, CSO
- Contact Info
Phone: (514) 788-7800
201 President-Kennedy Ave.
Montreal, H2X 3Y7
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.